Scholarlink

Purpose of review <p>We aim to evaluate the efficacy of risk-based surveillance strategies for hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) patients, addressing key questions: How can risk stratification enhance early detection? What are cost-effective approaches across diverse settings? How may novel diagnostic tools enhance surveillance?</p> Recent findings <p>Recent studies highlight a persistent risk of HCC despite antiviral therapy, with reported annual incidences of 0.01–5.4% depending on cirrhosis status. Validated scores (e.g., PAGE-B, mPAGE-B, REAL-B) improve risk stratification, while liver stiffness measurement (LSM) and biomarkers, such as GALAD, enhance detection sensitivity, ranging from 54% to 91%. Economic analyses support cost-effectiveness when annual HCC risk ≥ 0.2%, with ultrasound ± AFP as the surveillance backbone. Advanced modalities like CT/MRI and liquid biopsies have shown promise, while AI-driven models and virologic markers (e.g., HBcrAg) are emerging as dynamic predictors.</p> Summary <p>Risk-based surveillance, guided by scores and LSM, effectively targets high-risk HBV patients, reducing mortality and optimizing resources. These emerging tools hold promise for earlier detection, but validation and cost-effectiveness require further research. This approach will impact future studies by prioritizing personalized, globally adaptable strategies to achieve HBV elimination goals.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Hepatitis B Virus and Hepatocellular Carcinoma: Risk-Based Surveillance Strategies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月29日

查看全文
  • Abdelrahman M. Attia,
  • Jessica Liu,
  • Walid S Ayoub,
  • Yun Wang,
  • Aarshi Vipani,
  • Paul Martin,
  • Hyunseok Kim,
  • Ju Dong Yang

摘要

Purpose of review

We aim to evaluate the efficacy of risk-based surveillance strategies for hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) patients, addressing key questions: How can risk stratification enhance early detection? What are cost-effective approaches across diverse settings? How may novel diagnostic tools enhance surveillance?

Recent findings

Recent studies highlight a persistent risk of HCC despite antiviral therapy, with reported annual incidences of 0.01–5.4% depending on cirrhosis status. Validated scores (e.g., PAGE-B, mPAGE-B, REAL-B) improve risk stratification, while liver stiffness measurement (LSM) and biomarkers, such as GALAD, enhance detection sensitivity, ranging from 54% to 91%. Economic analyses support cost-effectiveness when annual HCC risk ≥ 0.2%, with ultrasound ± AFP as the surveillance backbone. Advanced modalities like CT/MRI and liquid biopsies have shown promise, while AI-driven models and virologic markers (e.g., HBcrAg) are emerging as dynamic predictors.

Summary

Risk-based surveillance, guided by scores and LSM, effectively targets high-risk HBV patients, reducing mortality and optimizing resources. These emerging tools hold promise for earlier detection, but validation and cost-effectiveness require further research. This approach will impact future studies by prioritizing personalized, globally adaptable strategies to achieve HBV elimination goals.